Comparative Pharmacology
Head-to-head clinical analysis: LYRICA versus VIGAFYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYRICA versus VIGAFYDE.
LYRICA vs VIGAFYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the α2-δ subunit of voltage-gated calcium channels, reducing calcium influx and inhibiting release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P.
Irreversible inhibitor of GABA transaminase, increasing brain GABA levels.
Oral: 75-150 mg twice daily or 50-100 mg three times daily; maximum 600 mg/day. Start at 75 mg twice daily.
Adults: 50 mg/kg/day orally divided twice daily; maximum dose 3 g/day.
None Documented
None Documented
Terminal elimination half-life is 6.3 hours (range 5.5–6.7 hours) in patients with normal renal function. Half-life increases in renal impairment (up to 48 hours in anuria).
Terminal elimination half-life is 6-8 hours in adults; in neonates, it is prolonged to 16-20 hours due to immature renal function.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; less than 1% is secreted in feces or bile. Dose adjustment required in renal impairment (CrCl <60 mL/min).
Renal excretion of unchanged drug accounts for approximately 65-70% of elimination; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant